IMMUNOTHERAPY DRUGS INDUSTRY MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: BYR-196435 | Pharmaceuticals
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
Immunotherapy Drugs Industry Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL IMMUNOTHERAPY DRUGS INDUSTRY MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL IMMUNOTHERAPY DRUGS INDUSTRY MARKET
7.1 GLOBAL IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA IMMUNOTHERAPY DRUGS INDUSTRY MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Janssen Global Services LLC
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 AstraZeneca
16.3 Novartis
16.4 Merck
16.5 Bristol-Myers Squibb
16.6 Bayer AG
16.7 Pfizer
16.8 Eli Lilly and Company
16.9 FHoffmann-La Roche AG
16.10 Amgen
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
Market by Type :Monoclonal Antibodies
Adult Vaccines
Checkpoint Inhibitors
Interferons Alpha & Beta
Interleukins
Other Drugs
Market by Application :
Cancer
Autoimmune & Inflammatory Diseases
Infectious Diseases
Other Therapy Area
Companies
Janssen Global Services LLC
AstraZeneca
Novartis
Merck
Bristol-Myers Squibb
Bayer AG
Pfizer
Eli Lilly and Company
FHoffmann-La Roche AG
Amgen
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.